Ileocolitis Research Services

Ileocolitis is the most common type of Crohn's disease. It causes inflammation in the end of the small intestine (ileum) and a portion of the large intestine (colon). It is the most common type of Crohn's disease. Around 50% of people with Crohn's disease are diagnosed with ileocolitis. People with the ileocolitis form of Crohn's have a variety of symptoms, including anemia, cramping, diarrhea, pain in the middle or lower right part of the abdomen, and significant weight loss. The precise cause of ileocolitis remains elusive and unknown. Furthermore, there is currently no treatment that can provide a permanent cure for this condition. As a result, continued research is necessary to better understand the underlying mechanisms and develop more effective therapeutic options.

Customized Studies for Ileocolitis

With a wealth of experience in preclinical ileocolitis studies, Ace Therapeutics is a trusted partner for your preclinical research. Our state-of-the-art facilities, coupled with animal models of Crohn's disease and extensive endpoint assays, allow you to gain a comprehensive understanding of ileocolitis pathogenesis and discover potential breakthroughs.

Diagnostic Development Services for Ileocolitis

Leverage our advanced customized services and open instrument platform to accelerate your diagnostic development process for ileocolitis. With years of experience working with life science, diagnostic, and pharmaceutical companies, our goal is to help clients make a smooth and timely transition from research to method development and validation.

• Animal model development and validation: We provide animal models that mimic key pathological features of ileocolitis.
• Biomarker discovery and validation: Screening of biomarker candidates with diagnostic value for ileocolitis using histological techniques (genome, transcriptome, proteome, metabolome, etc.).
• Biomarker detection: Establishment of standardized biomarker detection methods such as ELISA, mass spectrometry.
• Non-invasive imaging technology development: Evaluation of the application of intestinal imaging technologies such as magnetic resonance imaging (MRI) and electromagnetic scanning in animal models for the diagnosis of ileocolitis.

Drug Development Services for Ileocolitis

With years of experience in the field of Crohn's disease, we have a professional R&D team and advanced experimental platforms to provide high-quality drug development solutions for ileocolitis. We help clients develop various types of drugs for ileocolitis, including antibiotics, biologic therapies, corticosteroids, immunomodulators, and targeted synthetic small molecules.

Targeted Molecule Screening and Validation

• In-depth study of the pathogenesis of ileocolitis, including key aspects of immune regulation and inflammatory signaling pathways.
• We utilize bioinformatics and phenotypic screening to comprehensively screen target molecules with therapeutic potential.
• Validating the pharmacological properties and therapeutic efficacy of candidate targets in cell and animal models.

Lead Compound Design and Optimization

• Conducting virtual screening based on the target structure to find lead compounds with good druggability.
• Optimizing the activity, selectivity and metabolic stability of the lead compounds.
• Evaluating the pharmacokinetics and safety of the lead compounds in vitro and in vivo.

Optimization of Drug Delivery Modes

• Exploring novel drug delivery routes such as localized drug delivery and sustained release formulations to improve drug targeting and retention in the intestine.
• Evaluating the effects of different dosage forms on drug absorption, distribution, metabolism and excretion.

Drug Efficacy Evaluation

Test the efficacy of drug candidates in the treatment of ileocolitis in animal models.

Ace Therapeutics actively collaborates with researchers and pharmaceutical companies committed to ileocolitis research. Our extensive experience and specialized disease models allow us to provide a comprehensive and tailored approach to the preclinical development of your novel ileocolitis therapy. Contact us today to learn more!